Showing 1 - 20 results of 9,019 for search '(( significant benefits decrease ) OR ( significant ((level decrease) OR (greatest decrease)) ))', query time: 0.73s Refine Results
  1. 1
  2. 2

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”
  3. 3

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”
  4. 4

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”
  5. 5
  6. 6

    Green Hydrogen Economy: Scenarios versus Technologies by Hua Fan (495346)

    Published 2025
    “…Scenarios employing off-grid renewable energy without battery storage, coupled with low-capital-expenditure electrolyzers and optimized maintenance, offer the greatest cost benefits. This framework provides a basis for green hydrogen system design, highlighting the critical role of operational optimization in accelerating cost-effective deployment.…”
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17

    Metabolites with decreasing levels during the development. by Martin Sládek (130663)

    Published 2025
    “…<p>Temporal profiles of polar metabolites and lipids with SCN levels significantly decreasing from E19 to P28. Rhythmicity was determined by eJTK; full or dashed lines depict the profiles that either did or did not pass the significance threshold (FDR-adjusted <i>P</i> < 0.05), respectively.…”
  18. 18
  19. 19
  20. 20